75944 Federal Register / Vol. 65, No. 234 / Tuesday, December 5, 2000 / Notices

terminate two years from the signing

date unless renewed by the Secretary.

DATES: Nominations for members will

be considered if we receive them at the

appropriate address, as provided below,

before 5 p.m. on December 26, 2000.

ADDRESSES: Mail written nominations

for membership to the following address

ONLY: Health Care Financing

Administration, Department of Health

and Human Services, Attention: HCFA–

1162–N, P.O. Box 8013, Baltimore, MD

21244–8013.

If you prefer, you may deliver, by

courier, your written nominations to

one of the following addresses: Hubert

H. Humphrey Building, Room 443–G,

200 Independence Avenue, SW.,

Washington, DC 20201, or Health Care

Financing Administration, Room C5–

14–03, Central Building, 7500 Security

Boulevard, Baltimore, MD 21244–1850.

Nominations mailed to those

addresses designated for courier

delivery may be delayed and could be

considered late. Because of staffing and

resource limitations, we cannot accept

nominations by facsimile (FAX) or

email transmission. Please refer to file

code HCFA–1162–N on each

nomination.

You may receive a copy of the

Secretary’s charter for the panel by

mailing a written request to the

following address: Health Care

Financing Administration, Department

of Health and Human Services,

Attention: HCFA–1162–N, P.O. Box

8013, Baltimore, MD 21244–8013.

FOR FURTHER INFORMATION CONTACT: Paul

Olenick, (410) 786–0282.

SUPPLEMENTARY INFORMATION:

I. Background

The requirement for the Secretary to

consult with an outside Advisory Panel

on Ambulatory Payment Classification

(APC) Groups is set forth in section

1833(t)(9)(A) of the Social Security Act

(the Act), as added by section 201(h)

and redesignated by section 202(a)(2) of

the Balanced Budget Refinement Act of

1999 (BBRA 1999). The Secretary signed

the charter establishing the panel on

November 21, 2000. The charter will

terminate two years from the signing

date unless renewed by the Secretary.

The purpose of the panel is to review,

and advise the Secretary and the

Administrator of the Health Care

Financing Administration (HCFA)

concerning, the clinical integrity of the

APC groups and associated weights. The

panel consists of up to 15 members,

selected by the Secretary or a designee,

and a Chair, who is a government

official appointed by the Secretary.

The panel meets once each calendar

year in January or February so that we

may consider its advice when we

prepare the Annual Notice of Proposed

Rulemaking for changes to the hospital

outpatient prospective payment system

(OPPS). The work of the panel is

technical in nature and will concentrate

on the operational aspects of the APC

system. We will prepare the agenda for

the panel’s activities, which will set the

boundaries for discussion, and will

include issues such as the following:

• The determination as to whether

selected procedures are similar both

clinically and in terms of resource use.

• The assignment of new HCFA

Common Procedure Coding System

(HCPCS) codes to new or existing APCs.

• The reassignment of HCPCS codes

to different APCs.

• The reconfiguring of existing APCs

into new APCs.

The panel will not make policy

recommendations and will not discuss

items not on the agenda. Items that will

not be considered for the agenda

include the following, as well as other

items that are determined by us to be

outside the technical scope of the

panel’s activities:

• The conversion factor.

• The OPPS wage adjustments.

• The outlier or transitional corridor

payments.

• The transitional pass-through

payments for medical devices, drugs,

and biologicals.

In order to obtain the broadest

possible input for its work, the panel

must consult with entities and

organizations, such as the medical

device and drug industries, with expert

technical knowledge of the components

of the APCs. The panel may use data

collected or developed from entities and

organizations other than the Department

of Health and Human Services and

HCFA in conducting its review.

We are requesting nominations for

members to serve on the panel. Panel

members serve without compensation,

although travel, meals, lodging, and

related expenses will be reimbursed in

accordance with standard government

travel regulations. We have a special

interest in ensuring that women,

minorities, and the physically

challenged are adequately represented

on the panel and encourage

nominations of qualified candidates

from those groups.

II. Criteria for Nominees

Nominees must be representatives of

Medicare providers (including

Community Mental Health Centers)

subject to the OPPS, with technical and/

or clinical expertise in any of the

following areas:

• Hospital payment systems.

• Hospital medical care delivery

systems.

• Outpatient payment requirements.

• Ambulatory payment classification

groups.

• Use of, and payment for, drugs and

medical devices in an outpatient setting.

• Provision of, and payment for,

partial hospitalization services.

• Any other relevant expertise.

It is not necessary that any nominee

possess expertise in all of the areas

listed, but each must have a minimum

of five years experience, and currently

be employed full-time, in his or her area

of expertise. Members of the panel serve

overlapping four-year terms, contingent

upon the rechartering of the panel.

Any interested person may nominate

one or more qualified individuals. Selfnominations will also be accepted. Each

nomination must include a letter of

nomination, a curriculum vita of the

nominee, and a statement from the

nominee that the nominee is willing to

serve on the panel.

Authority: Section 1833(t)(9)(A) of the

Social Security Act (42 U.S.C. 1395(t)).

Dated: November 29, 2000.

Michael M. Hash,

Acting Administrator, Health, Care Financing

Administration

[FR Doc. 00–30994 Filed 12–1–00; 12:21 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

Federal Register / Vol. 65, No. 234 / Tuesday, December 5, 2000 / Notices 75945

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be listed at the end, and will be omitted

from the monthly listing thereafter.

This Notice is also available on the

internet at the following website:

http://www.health.org/workplace

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014, Fax: (301) 443–

3031.

Special Note: Please use the above

address for all surface mail and

correspondence. For all overnight mail

service use the following address:

Division of Workplace Programs, 5515

Security Lane, Room 815, Rockville,

Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave.,

West Allis, WI 53227, 414–328–7840/800–

877–7016, (Formerly: Bayshore Clinical

Laboratory).

Advanced Toxicology Network, 3560 Air

Center Cove, Suite 101, Memphis, TN

38118, 901–794–5770/888–290–1150.

Aegis Analytical Laboratories, Inc., 345 Hill

Ave., Nashville, TN 37210, 615–255–2400.

Alabama Reference Laboratories, Inc., 543

South Hull St., Montgomery, AL 36103,

800–541–4931/334–263–5745.

Alliance Laboratory Services, 3200 Burnet

Ave., Cincinnati, OH 45229, 513–585–

9000, (Formerly: Jewish Hospital of

Cincinnati, Inc.).

American Medical Laboratories, Inc., 14225

Newbrook Dr., Chantilly, VA 20151 703–

802–6900.

Associated Pathologists Laboratories, Inc.,

4230 South Burnham Ave., Suite 250, Las

Vegas, NV 89119–5412, 702–733–7866/

800–433–2750.

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little Rock,

AR 72205–7299, 501–202–2783, (Formerly:

Forensic Toxicology Laboratory Baptist

Medical Center).

Clinical Laboratory Partners, LLC 129 East

Cedar St. Newington, CT 06111, 860–696–

8115, (Formerly: Hartford Hospital

Toxicology Laboratory).

Clinical Reference Lab, 8433 Quivira Rd.,

Lenexa, KS 66215–2802, 800–445–6917.

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson Ave.,

Springfield, MO 65802, 800–876–3652/

417–269–3093, (Formerly: Cox Medical

Centers).

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building 38–H,

P. O. Box 88–6819, Great Lakes, IL 60088–

6819, 847–688–2045/847–688–4171.

Diagnostic Services Inc., dba DSI, 12700

Westlinks Drive, Fort Myers, FL 33913,

941–561–8200/800–735–5416.

Doctors Laboratory, Inc., P.O. Box 2658, 2906

Julia Dr., Valdosta, GA, 31602 912–244–

4468.

DrugProof, Division of Dynacare/Laboratory

of Pathology, LLC 1229 Madison St., Suite

500, Nordstrom Medical Tower, Seattle,

WA 98104, 206–386–2672/800–898–0180

(Formerly: Laboratory of Pathology of

Seattle, Inc. DrugProof, Division of

Laboratory of Pathology of Seattle, Inc.).

DrugScan, Inc., P.O. Box 2969, 1119 Mearns

Rd., Warminster, PA 18974, 215–674–9310.

Dynacare Kasper Medical Laboratories*,

14940–123 Ave., Edmonton, Alberta,

Canada T5V 1B4, 780–451–3702/800–661–

9876.

ElSohly Laboratories, Inc., 5 Industrial Park

Dr., Oxford, MS 38655, 662–236–2609.

Express Analytical Labs, 1301 18th Ave NW,

Suite 110, Austin, MN 55912, 507–437–

7322.

Gamma-Dynacare Medical Laboratories*, A

Division of the Gamma-Dynacare

Laboratory Partnership, 245 Pall Mall St.,

London, ONT, Canada N6A 1P4, 519–679–

1630.

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–267–

6267.

Integrated Regional Laboratories, 5361 NW

33rd Avenue, Fort Lauderdale, FL 33309,

954–777–0018, 800–522–0232, (Formerly:

Cedars Medical Center, Department of

Pathology).

Kroll Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–361–

8989/800–433–3823, (Formerly: Laboratory

Specialists, Inc.).

LabOne, Inc., 10101 Renner Blvd., Lenexa,

KS 66219, 913–888–3927/800–728–4064,

(Formerly: Center for Laboratory Services,

a Division of LabOne, Inc.).

Laboratory Corporation of America Holdings,

7207 N. Gessner Road, Houston, TX 77040,

713–856–8288/800–800–2387.

Laboratory Corporation of America Holdings,

1904 Alexander Drive, Research Triangle

Park, NC 27709, 919–572–6900/800–833–

3984, (Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem

Laboratories, Inc.; CompuChem

Laboratories, Inc., A Subsidiary of Roche

Biomedical Laboratory; Roche

CompuChem Laboratories, Inc., A Member

of the Roche Group).

Laboratory Corporation of America Holdings,

4022 Willow Lake Blvd., Memphis, TN

38118, 866–827–8042/800–233–6339,

(Formerly: LabCorp Occupational Testing

Services, Inc., MedExpress/National

Laboratory Center).

Laboratory Corporation of America Holdings,

69 First Ave., Raritan, NJ 08869, 908–526–

2400/800–437–4986, (Formerly: Roche

Biomedical Laboratories, Inc.).

Marshfield Laboratories, Forensic Toxicology

Laboratory, 1000 North Oak Ave.,

Marshfield, WI 54449, 715–389–3734/800–

331–3734.

MAXXAM Analytics Inc.*, 5540 McAdam

Rd., Mississauga, ON, Canada L4Z 1P1,

905–890–2555, (Formerly: NOVAMANN

(Ontario) Inc.).

Medical College Hospitals Toxicology

Laboratory, Department of Pathology, 3000

Arlington Ave., Toledo, OH 43699, 419–

383–5213.

MedTox Laboratories, Inc., 402 W. County

Rd. D, St. Paul, MN 55112, 651–636–7466/

800–832–3244.

MetroLab-Legacy Laboratory Services, 1225

NE 2nd Ave., Portland, OR 97232, 503–

413–5295/800–950–5295.

Minneapolis Veterans Affairs Medical Center,

Forensic Toxicology Laboratory, 1 Veterans

Drive, Minneapolis, Minnesota 55417,

612–725–2088.

National Toxicology Laboratories, Inc., 1100

California Ave., Bakersfield, CA 93304,

661–322–4250/800–350–3515.

NWT Drug Testing, 1141 E. 3900 South, Salt

Lake City, UT 84124, 801–293–2300/800–

322–3361, (Formerly: NorthWest

Toxicology, Inc.).

One Source Toxicology Laboratory, Inc., 1705

Center Street, Deer Park, TX 77536, 713–

920–2559, (Formerly: University of Texas

Medical Branch, Clinical Chemistry

Division; UTMB Pathology-Toxicology

Laboratory).

Oregon Medical Laboratories, P.O. Box 972,

722 East 11th Ave., Eugene, OR 97440–

0972, 541–687–2134.

Pacific Toxicology Laboratories, 6160 Variel

Ave., Woodland Hills, CA 91367, 818–598–

3110/800–328–6942, (Formerly: Centinela

Hospital Airport Toxicology Laboratory).

Pathology Associates Medical Laboratories,

11604 E. Indiana Ave., Spokane, WA

99206, 509–926–2400/800–541–7891.

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025, 650–

328–6200/800–446–5177.

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth, TX

76118, 817–215–8800, (Formerly: Harris

Medical Laboratory).

75946 Federal Register / Vol. 65, No. 234 / Tuesday, December 5, 2000 / Notices

Physicians Reference Laboratory, 7800 West

110th St., Overland Park, KS 66210, 913–

339–0372/800–821–3627.

Poisonlab, Inc., 7272 Clairemont Mesa Blvd.,

San Diego, CA 92111, 858–279–2600/800–

882–7272.

Quest Diagnostics Incorporated, 3175

Presidential Dr., Atlanta, GA 30340, 770–

452–1590, (Formerly: SmithKline Beecham

Clinical Laboratories, SmithKline BioScience Laboratories).

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI 48326,

248–373–9120/800–444–0106, (Formerly:

HealthCare/Preferred Laboratories,

HealthCare/MetPath, CORNING Clinical

Laboratories).

Quest Diagnostics Incorporated, 8000

Sovereign Row, Dallas, TX 75247, 214–

638–1301, (Formerly: SmithKline Beecham

Clinical Laboratories, SmithKline BioScience Laboratories).

Quest Diagnostics Incorporated, 4770 Regent

Blvd., Irving, TX 75063, 972–916–3376/

800–526–0947, (Formerly: Damon Clinical

Laboratories, Damon/MetPath, CORNING

Clinical Laboratories).

Quest Diagnostics Incorporated, 801 East

Dixie Ave., Suite 105A, Leesburg, FL

34748, 352–787–9006x4343, (Formerly:

SmithKline Beecham Clinical Laboratories,

Doctors & Physicians Laboratory).

Quest Diagnostics Incorporated, 400 Egypt

Rd., Norristown, PA 19403, 610–631–4600/

800–877–7484, (Formerly: SmithKline

Beecham Clinical Laboratories, SmithKline

Bio-Science Laboratories).

Quest Diagnostics Incorporated, 506 E. State

Pkwy., Schaumburg, IL 60173, 800–669–

6995/847–885–2010, (Formerly:

SmithKline Beecham Clinical Laboratories,

International Toxicology Laboratories).

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA 92108–

4406, 619–686–3200/800–446–4728,

(Formerly: Nichols Institute, Nichols

Institute Substance Abuse Testing (NISAT),

CORNING Nichols Institute, CORNING

Clinical Laboratories).

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608, 201–

393–5590, (Formerly: MetPath, Inc.,

CORNING MetPath Clinical Laboratories,

CORNING Clinical Laboratory).

Quest Diagnostics Incorporated, 7600 Tyrone

Ave., Van Nuys, CA 91405, 818–989–2520/

800–877–2520, (Formerly: SmithKline

Beecham Clinical Laboratories).

San Diego Reference Laboratory, 6122 Nancy

Ridge Dr., San Diego, CA 92121, 800–677–

7995/858–677–7970.

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA 23236,

804–378–9130.

Scott & White Drug Testing Laboratory, 600

S. 25th St., Temple, TX 76504, 254–771–

8379/800–749–3788.

S.E.D. Medical Laboratories, 5601 Office

Blvd., Albuquerque, NM 87109, 505–727–

6300/800–999–5227.

South Bend Medical Foundation, Inc., 530 N.

Lafayette Blvd., South Bend, IN 46601,

219–234–4176.

Southwest Laboratories, 2727 W. Baseline

Rd., Tempe, AZ 85283, 602–438–8507/

800–279–0027.

Sparrow Health System, Toxicology Testing

Center, St. Lawrence Campus, 1210 W.

Saginaw, Lansing, MI 48915, 517–377–

0520, (Formerly: St. Lawrence Hospital &

Healthcare System).

St. Anthony Hospital Toxicology Laboratory,

1000 N. Lee St., Oklahoma City, OK 73101,

405–272–7052.

Toxicology & Drug Monitoring Laboratory,

University of Missouri Hospital & Clinics,

2703 Clark Lane, Suite B, Lower Level,

Columbia, MO 65202, 573–882–1273.

Toxicology Testing Service, Inc., 5426 N.W.

79th Ave., Miami, FL 33166, 305–593–

2260.

UNILAB, 18408 Oxnard St., Tarzana, CA

91356, 818–996–7300/800–339–4299,

(Formerly: MetWest-BPL Toxicology

Laboratory).

Universal Toxicology Laboratories, LLC, 9930

W. Highway 80, Midland, TX 79706, 915–

561–8851/888–953–8851.

*The Standards Council of Canada (SCC)

voted to end its Laboratory Accreditation

Program for Substance Abuse (LAPSA)

effective May 12, 1998. Laboratories certified

through that program were accredited to

conduct forensic urine drug testing as

required by U.S. Department of

Transportation (DOT) regulations. As of that

date, the certification of those accredited

Canadian laboratories will continue under

DOT authority. The responsibility for

conducting quarterly performance testing

plus periodic on-site inspections of those

LAPSA-accredited laboratories was

transferred to the U.S. DHHS, with the

DHHS’ National Laboratory Certification

Program (NLCP) contractor continuing to

have an active role in the performance testing

and laboratory inspection processes. Other

Canadian laboratories wishing to be

considered for the NLCP may apply directly

to the NLCP contractor just as U.S.

laboratories do. Upon finding a Canadian

laboratory to be qualified, the DHHS will

recommend that DOT certify the laboratory

(Federal Register, 16 July 1996) as meeting

the minimum standards of the ‘‘Mandatory

Guidelines for Workplace Drug Testing’’ (59

FR, 9 June 1994, Pages 29908–29931). After

receiving the DOT certification, the

laboratory will be included in the monthly

list of DHHS certified laboratories and

participate in the NLCP certification

maintenance program.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 00–30854 Filed 12–4–00; 8:45 am]

BILLING CODE 4160–20–U

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Availability of a Draft Environmental

Impact Statement and Receipt of an

Application for an Incidental Take

Permit for the Metro Air Park Project in

the Natomas Basin, Sacramento

County, California

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice of Availability.

SUMMARY: The Metro Air Park Property

Owners Association (Association) has

applied to the Fish and Wildlife Service

(Service) for an incidental take permit

pursuant to section 10(a)(1)(B) of the

Endangered Species Act of 1973, as

amended (Act). The Association, a nonprofit mutual benefit corporation, has

applied on behalf of 138 individual

property owners within the Metro Air

Park 1,892-acre Special Planning Area

who wish to pursue development of

urban uses and rice farming on these

lands. The development area is in the

Natomas Basin, Sacramento County,

California, with associated mitigation

lands for Metro Air Park development

within Sacramento and Sutter Counties,

California. The proposed permit would

authorize incidental take of three

federally listed species. The proposed

taking of these species would be

incidental to the implementation of the

Metro Air Park Habitat Conservation

Plan (Plan), which provides for the

development of the Metro Air Park

industrial park project along with the

continuation of rice farming activities.

The proposed permit also would

authorize future incidental take of 10

currently unlisted species, should any

of them become listed under the Act

during the life of the permit. The

proposed permit duration is 50 years.

The permit application, available for

public review, includes the Plan which

describes the proposed program and

mitigation, and an accompanying

Implementing Agreement.

The Service also announces the

availability of a Draft Environmental

Impact Statement for the incidental take

permit application. All comments

received, including names and

addresses, will become part of the

official administrative record and may

be made available to the public.

Public Meeting: A public meeting will

be held on January 8, 2001, from 7 p.m.

to 9 p.m. at the County of Sacramento,

Hearing Room 1, 700 H Street,

Sacramento, California, 95814. For

additional meeting information, contact

Ms. Vicki Campbell, Chief, Conservation